Global Network = Global Treatment
The MEF2C Brain Trust
Our therapeutic development strategy is guided by our Brain Trust of MEF2C focused scientists, academics, and clinicians who are helping us identify, develop and seed research for therapeutic candidates. As we navigate this journey, we rely on our Brain Trust to apply their collective expertise to navigate the challenges of the development process.
The MEF2C Brain Trust features leading experts in MEF2C and rare disease therapeutics from:
The University of Texas Southwestern Medical Center
The Medical University of South Carolina
Stanford University
The Jackson Laboratory
Baylor College of Medicine
Cornell University Weill School of Medicine
Global reach, global network
Recognizing the international impact of MCHS, Rare Bird embraces a global vision of MEF2C therapeutic development while leveraging our U.S. presence and expert team to advance our mission.
We partner with our colleagues at MEF2C non-profits worldwide to ensure that the needs of our global population are at the forefront of what we do.
Our clinical readiness, clinical trial, and regulatory efforts are focused on maximizing reach, involvement, and inclusivity.